$3.01
+0.00 (+0.00%)
Open$2.99
Previous Close$3.01
Day High$3.08
Day Low$2.86
52W High$5.55
52W Low$1.02
Volume—
Avg Volume2.24M
Market Cap190.70M
P/E Ratio—
EPS$-0.93
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,404.7% upside
Current
$3.01
$3.01
Target
$45.29
$45.29
$33.37
$45.29 avg
$67.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.13M | 59.72M | 61.79M |
| Net Income | -81,177,378 | -17,457,928 | -16,293,891 |
| Profit Margin | -574.6% | -29.2% | -26.4% |
| EBITDA | -83,927,006 | -19,228,267 | -21,164,861 |
| Free Cash Flow | — | -18,637,383 | -17,592,445 |
| Rev Growth | — | -4.4% | +5.4% |
| Debt/Equity | 0.00 | 0.30 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |